These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

701 related items for PubMed ID: 20399042

  • 1. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X, Servitja S, Peña MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L, Albanell J, Diez-Perez A, Tusquets I.
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [Abstract] [Full Text] [Related]

  • 2. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Servitja S, Nogués X, Prieto-Alhambra D, Martínez-García M, Garrigós L, Peña MJ, de Ramon M, Díez-Pérez A, Albanell J, Tusquets I.
    Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
    [Abstract] [Full Text] [Related]

  • 3. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE.
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [Abstract] [Full Text] [Related]

  • 4. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE.
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
    Rhee Y, Song K, Park S, Park HS, Lim SK, Park BW.
    Endocr J; 2013 Mar; 60(2):167-72. PubMed ID: 23064476
    [Abstract] [Full Text] [Related]

  • 6. Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
    Sergi G, Pintore G, Falci C, Veronese N, Berton L, Perissinotto E, Basso U, Brunello A, Monfardini S, Manzato E, Coin A.
    J Bone Miner Metab; 2012 Jul; 30(4):461-7. PubMed ID: 22160398
    [Abstract] [Full Text] [Related]

  • 7. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
    Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O'Dea AP, Klemp JR, Fabian CJ.
    Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
    [Abstract] [Full Text] [Related]

  • 8. [Relationship between vitamin D status and bone mineral density in Croatian postmenopausal women].
    Laktasić-Zerjavić N, Rukavina K, Babić-Naglić D, Curković B, Anić B, Soldo-Juresa D.
    Reumatizam; 2013 Jan; 60(1):8-13. PubMed ID: 24003677
    [Abstract] [Full Text] [Related]

  • 9. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A, FOCUS-D Investigators.
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [Abstract] [Full Text] [Related]

  • 10. Practical guidance for the management of aromatase inhibitor-associated bone loss.
    Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M.
    Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. AI-related BMD variation in actual practice conditions: A prospective cohort study.
    Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Garcia-Giralt N, Garrigos L, Rodriguez-Morera J, Albanell J, Martínez-García M, González I, Diez-Perez A, Tusquets I, Nogués X.
    Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy.
    Knobf MT, Jeon S, Smith B, Harris L, Kerstetter J, Thompson AS, Insogna K.
    Breast Cancer Res Treat; 2016 Feb; 155(3):491-500. PubMed ID: 26850265
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate.
    Catalano A, Morabito N, Di Stefano A, Morini E, Basile G, Faraci B, Loddo S, Ientile R, Lasco A.
    J Endocrinol Invest; 2015 Aug; 38(8):859-63. PubMed ID: 25952299
    [Abstract] [Full Text] [Related]

  • 19. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.